Thomas Yip
Recent Quotes
"CPXX's CombiPlex could improve the therapeutic index of MTA combinations."
—
Thomas Yip, FBR Capital Markets
(9/24/15)
more >
"CPXX guides to a Q1/16 data readout from the Phase 3 Vyxeos trial."
—
Thomas Yip, MLV & Co
(8/12/15)
more >
"OMER's Omidria is one step closer to European Union approval."
—
Thomas Yip, MLV & Co
(5/26/15)
more >
Due to permission requirements, not all quotes are shown.
